0001493152-23-025150.txt : 20230720 0001493152-23-025150.hdr.sgml : 20230720 20230720194817 ACCESSION NUMBER: 0001493152-23-025150 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230718 FILED AS OF DATE: 20230720 DATE AS OF CHANGE: 20230720 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BAUM MARK L CENTRAL INDEX KEY: 0001274282 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35814 FILM NUMBER: 231100818 MAIL ADDRESS: STREET 1: C/O IMPRIMIS PHARMACEUTICALS, INC STREET 2: 12264 EL CAMINO REAL, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HARROW HEALTH, INC. CENTRAL INDEX KEY: 0001360214 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 450567010 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 102 WOODMONT BLVD STREET 2: SUITE 610 CITY: NASHVILLE STATE: TN ZIP: 37215 BUSINESS PHONE: 615.733.4731 MAIL ADDRESS: STREET 1: 102 WOODMONT BLVD STREET 2: SUITE 610 CITY: NASHVILLE STATE: TN ZIP: 37215 FORMER COMPANY: FORMER CONFORMED NAME: Imprimis Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20120301 FORMER COMPANY: FORMER CONFORMED NAME: TRANSDEL PHARMACEUTICALS INC DATE OF NAME CHANGE: 20070912 FORMER COMPANY: FORMER CONFORMED NAME: Bywater Resources, Inc DATE OF NAME CHANGE: 20060421 4 1 ownership.xml X0508 4 2023-07-18 0 0001360214 HARROW HEALTH, INC. HROW 0001274282 BAUM MARK L C/O HARROW HEALTH, INC. 102 WOODMONT BLVD, SUITE 610 NASHVILLE TN 37205 1 1 0 0 Chief Executive Officer 0 Common Stock 2023-07-18 4 M 0 762300 A 2309629 D Common Stock 2023-07-18 4 F 0 299968 18.23 D 2009661 D Performance Stock Unit 2023-07-18 4 M 0 762300 0 D Common Stock 762300 0 D The 762,300 shares of Harrow Health, Inc. ("Harrow") common stock listed in Table I as "Acquired" represent shares issued based on vesting of performance stock units ("PSUs") granted to Mr. Baum under Harrow's 2017 Stock Incentive and Awards Plan (the "Incentive Plan") on July 23, 2021. The PSUs were settled in full (on a one-for-one basis) on July 18, 2023, following attainment of total stockholder return targets ranging from 50% - 175 % following the date of the award. The 299,968 shares of Harrow common stock listed in Table I as "Disposed" were not sold by Mr. Baum in any transaction; rather, they were shares of Harrow common stock withheld by the Company for payroll tax purposes from the same aforementioned 762,300 shares pursuant to the terms of the Incentive Plan. /s/ Mark L. Baum 2023-07-20